MedTrace Logo

Cardiac Amyloidosis in HFpEF Tunisian Patients

NCT06201832 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2026-05-19

No results posted yet for this study

Summary

Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations.

Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis.

In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.

Conditions

Sponsors & Collaborators

  • University Tunis El Manar

    lead OTHER

Principal Investigators

  • Lilia Zakhama, Prof · University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201832 on ClinicalTrials.gov